Amarin (AMRN) with relative strength and lower levels of implied volatility Friday after the FDA accepted the biotech’s New Drug Application for AMR101, a treatment for high triglyceride levels. Shares are up 37 cents to $7.04 and Dec 6 puts are the most actively traded options on the stock. 1750 traded (94 percent Bid). Dec 7 puts and Dec 8 calls are also seeing volume and trading predominatly on the bid. 2,280 puts and 1,115 calls traded on the stock and implied volatility is down 11 percent, but still elevated at 107.
About the Author (Author Profile)
Frederic Ruffy is a well-known trader, writer, and strategist who has spent years educating investors and creating intelligent, insightful, unbiased market observations that are frequently cited by the Wall Street Journal and other financial publications. As senior analyst, Fred provides frequent and regular notes and daily updates for activity of interest.